McPherson plant will produce Covid-19 drug that is in short supply

A Kansas manufacturing plant will help fill demand for remdesivir, a key drug used to treat Covid-19 patients. Pfizer Inc. said Friday it has an agreement to produce Gilead Sciences Inc.’s antiviral drug at a facility in McPherson, Kansas. The antiviral is an investigational drug that received emergency authorization by the Food and Drug Administration for treatment of patients with Covid-19. The drug has shown promise, but a shortage of remdesivir has caused authorities to ration its distribution to hospitals, and forced hospitals to ration its use to only the most serious patients. Pfizer will provide contract manufacturing of the drug as part of a multi-year agreement.
(Read more: Kansas City Business Journal)